AU1190901A - Replication selective adenoviruses for use in cancer therapy - Google Patents

Replication selective adenoviruses for use in cancer therapy

Info

Publication number
AU1190901A
AU1190901A AU11909/01A AU1190901A AU1190901A AU 1190901 A AU1190901 A AU 1190901A AU 11909/01 A AU11909/01 A AU 11909/01A AU 1190901 A AU1190901 A AU 1190901A AU 1190901 A AU1190901 A AU 1190901A
Authority
AU
Australia
Prior art keywords
cancer therapy
replication selective
adenoviruses
selective adenoviruses
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11909/01A
Inventor
Katherine Molnar-Kimber
Takane Toyoizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU1190901A publication Critical patent/AU1190901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU11909/01A 1999-09-30 2000-10-02 Replication selective adenoviruses for use in cancer therapy Abandoned AU1190901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15722499P 1999-09-30 1999-09-30
US60157224 1999-09-30
PCT/US2000/027212 WO2001023004A1 (en) 1999-09-30 2000-10-02 Replication selective adenoviruses for use in cancer therapy

Publications (1)

Publication Number Publication Date
AU1190901A true AU1190901A (en) 2001-04-30

Family

ID=22562838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11909/01A Abandoned AU1190901A (en) 1999-09-30 2000-10-02 Replication selective adenoviruses for use in cancer therapy

Country Status (2)

Country Link
AU (1) AU1190901A (en)
WO (1) WO2001023004A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
JP2004536572A (en) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド New vector construct
WO2003102186A1 (en) * 2002-05-31 2003-12-11 Medinet Co., Ltd. Dna inducing cancer cell-specific expression and cancer cell-specific expression vector
WO2005115476A1 (en) * 2004-05-25 2005-12-08 Univ Kurume Drug comprising as the active ingredient proliferative vector containing survivin promoter
US9624476B2 (en) 2011-08-23 2017-04-18 National Institute Of Biomedical Innovation Conditionally replicating adenovirus
CN103946885A (en) 2011-11-17 2014-07-23 拜耳医疗保健公司 Methods and techniques for collecting, reporting, and managing information about medical diagnostic procedures
SG10201604654RA (en) 2012-01-25 2016-07-28 Dnatrix Inc Biomarkers and combination therapies using oncolytic virus and immunomodulation
CA2863523A1 (en) 2012-02-02 2013-08-08 Juan FUEYO-MARGARETO Recombinant adenovirus expressing cancer antigens
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7054527B2 (en) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ High-throughput assay to measure adenovirus replication kinetics
KR20180112024A (en) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression of therapeutic adenoviruses for minimizing the effects on viral dynamics
CN110062630A (en) 2016-12-12 2019-07-26 萨克生物研究学院 Cancer target synthesizes adenovirus and application thereof
AU2018212017A1 (en) * 2017-01-30 2019-08-15 Epicentrx, Inc. Tumor selective TATA -box and CAAT-box mutants
EP3649648A1 (en) 2017-07-07 2020-05-13 Bayer Healthcare LLC System, method, and computer program product for peer exchange of data between injection systems
WO2019093435A1 (en) * 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene
CN111500632B (en) * 2020-04-28 2023-09-15 浙江理工大学绍兴生物医药研究院有限公司 Oncolytic adenovirus construction for expressing ST13 and TRAIL and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206179C (en) * 1994-11-28 2007-10-23 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors

Also Published As

Publication number Publication date
WO2001023004A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
AU1190901A (en) Replication selective adenoviruses for use in cancer therapy
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
AU2002258990A1 (en) Improvements in ablation therapy
GB9912411D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
IL206604A0 (en) Transmembrane protein expressed in prostate cancer
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU1453301A (en) Methods of reversing drug resistance in cancer cells
AU3301700A (en) (n)-sulfonyl-dipeptide derivatives, production and use thereof in therapy
GB9912410D0 (en) Compounds useful in therapy
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
GB9912415D0 (en) Compounds useful in therapy
AU1043901A (en) Flexible sheets for use in therapy
AU3808800A (en) Compounds for use in therapy
AU2001287884A1 (en) Halogen compounds for use in medicine
AU3060400A (en) Triazole and tetrazole derivatives, and their therapeutic use
AU2002210686A1 (en) Flavan compounds, their preparation and their use in therapy
AU2001236911A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy
AU2001269259A1 (en) Aryl compounds, their preparation and their use in therapy
AU2002316688A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy
AU2877799A (en) Natural product composition for use in treating cancer
AU5522499A (en) 2-aminoethyl-quinoline derivatives, preparation and therapeutic use
AUPP835099A0 (en) Bismuth-213 and terbium-149 immunoconjugates for therapy for cancer
AU2001228686A1 (en) Biaryl compounds, their preparation and their use in therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase